Related Experiment Video
Updated: Apr 24, 2026
06:59
Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
41.6K
Genetic variants of ApoE and ApoER2 differentially modulate endothelial function
Victoria Ulrich1, Eddy S Konaniah2, Joachim Herz3
1Center for Pulmonary and Vascular Biology, Department of Pediatrics, and.
Summary
Cardiovascular disease risk is linked to apolipoprotein E4 (apoE4) and ApoER2-R952Q variants. These impact endothelial cell function, affecting NO production, repair, and inflammation, unlike apoE3 which is protective.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Endothelial Function
Background:
- The apolipoprotein E4 (apoE4) allele increases cardiovascular disease (CVD) risk compared to apoE3.
- The LRP8/apolipoprotein E receptor 2 (ApoER2) variant ApoER2-R952Q is also associated with increased CVD risk.
- The function of the apoE-ApoER2 pathway in endothelial cells is not well understood.
Purpose of the Study:
- To investigate the differential roles of apoE3 and apoE4 in endothelial cells via ApoER2.
- To determine the functional consequences of the ApoER2-R952Q variant in endothelial cells.
- To elucidate the impact of apoE and ApoER2 variants on vascular repair and inflammation.
Main Methods:
- Endothelial cell culture experiments assessing eNOS activity, cell migration, and monocyte adhesion.
- Structural analysis of apoE isoforms.
- Reconstitution experiments with ApoER2 variants.
- In vivo studies using ApoER2 knockout mice and adenoviral gene transfer in wild-type mice.
- Assessment of carotid artery reendothelialization and neointima formation.
Main Results:
- ApoE3 binding to ApoER2 stimulates endothelial NO synthase (eNOS), promotes cell migration, and reduces monocyte adhesion.
- ApoE4 fails to stimulate eNOS or migration and antagonizes apoE3/ApoER2 actions.
- ApoER2-R952Q acts as a loss-of-function variant in endothelial cells.
- ApoER2(-/-) mice show impaired carotid artery reendothelialization and exaggerated neointima formation.
- ApoE4 impairs reendothelialization in vivo, while apoE3 has no effect.
Conclusions:
- The apoE3/ApoER2 tandem promotes endothelial NO production, repair, and anti-inflammatory properties, preventing neointima formation.
- ApoE4 and the ApoER2-R952Q variant exhibit dominant-negative and loss-of-function effects, respectively, contributing to cardiovascular risk.
- Genetic variations in apoE and ApoER2 significantly modulate endothelial function and impact cardiovascular health.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
155
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
186
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
186
01:29Pharmacogenomics: Identification of New Drug Targets
113
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
01:27Principles of Pharmacogenetics: Types of Genetic Variants
134
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
134
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
325
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
325